Entero Healthcare Solutions Limited has informed the Exchange regarding Board meeting held on February 12, 2026.
ENTERO · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 0.6 pts more than Nifty Microcap 250 and 0.6 pts more than its Retailing peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Entero Healthcare's board approved unaudited Q3 FY26 and nine-month results ended December 31, 2025, with the auditor issuing an unmodified (clean) opinion. On a consolidated basis, revenue from operations grew about 25.6% year-on-year to Rs 1,706.5 crore in Q3 and 24.6% to Rs 4,681.3 crore for 9M FY26, helped by multiple new subsidiary acquisitions during the year. Consolidated profit after tax rose roughly 32.5% to Rs 100.7 crore for 9M FY26, though Q3 PAT was up a milder 15% at Rs 33.9 crore. Standalone numbers were weak, with revenue down nearly 20% and PAT falling about 71% to Rs 13.5 crore for 9M FY26. The company booked an exceptional charge of Rs 8.18 crore (consolidated) linked to the new Labour Codes. The board also cancelled two earlier announced acquisitions (Khera Medisolutions and AV Medisolutions) due to commercial reasons and granted 5,000 fresh ESOPs at Rs 804 each. IPO proceeds have been fully utilised, and the consolidated results were filed without UDIN owing to portal maintenance, to be updated later.
Consolidated growth driven by acquisitions is a positive, but the sharp standalone decline, the new labour-code exceptional charge, and the cancellation of two acquisitions introduce some caution. Retail investors should watch whether the strong consolidated trajectory continues and how the standalone business stabilises.